Ipsen’s Dysport to treat a range of therapeutic indications

Ipsen has presented results of Dysport and botulinum toxins pipeline, from basic science to clinical phases, and patients and caregivers surveys, highlighting differentiation of Dysport in the treatment of spasticity and movement disorders.

The data is from results from the first in-human study of a recombinant neurotoxin (rBoNT-E), real life data (ULIS-III) as well as a survey with insights from patients and caregivers on the burden of spasticity (Carenity), Ipsen said.

Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said in a statement: “Our data at TOXINS 2019 further differentiate Dysport in the treatment of spasticity and other movement disorders, and demonstrate the headway we are making with our innovative pipeline, including new recombinant botulinum toxins such as our fast-acting rBoNT-E.”

Alexandre Lebeaut added that Ipsen will continue investing in this unique product through research and novel programs studies to further explore its potential and address patients’ unmet needs.